

FLORIDA SOCIETY OF CLINICAL ONCOLOGY

*A Year in Review*



2  
0  
2  
3



# LETTER FROM THE FLASCO PAST PRESIDENT



## Dear FLASCO Members & Partners,

Gratitude is a virtue of great value. We have a lot of things to be grateful for. It is with gratitude I end my term as president of FLASCO in 2023

Thankful for the fellow officers who guided the course of the organization. Thankful for the board members for their time and dedication. Thankful for our FLASCO Staff who tirelessly keep us always on the go. Thankful for our new office so we can grow and be more efficient. Thankful for our existing programs that show the three shields of FLASCO. Thankful for our industry partners who truly engage us and keep us on our toes. Thankful for our families for their love and care. Thankful that we can have a time of rest and peace as 2023 comes to a close.

Wishing all a joyful, blessed time of the year.

*"True happiness is to enjoy the present, without anxious dependence upon the future, not to amuse ourselves with either hopes or fears but to rest satisfied with what we have, which is sufficient, for he that is so wants nothing. The greatest blessings of mankind are within us and within our reach. A wise man is content with his lot, whatever it may be, without wishing for what he has not." — Seneca*

**Best Regards,**

**Winston Tan, MD**

Past President 2021-2023



# MISSION & VISION

The Florida Society of Clinical Oncology is a statewide non-profit organization committed to facilitating and promoting multidisciplinary efforts to improve patient care in Florida by:



- Fostering access to quality cancer care to the citizens of Florida.
- Assisting cancer practitioners in providing the most cost effective quality care for their patients.
- Acting as an advocate for Florida cancer patients and their families.
- Coordinating the dissemination of information and providing an opportunity for oncologists, physicians, and other health care professionals to network and exchange information.

---

## MEASURING PROGRESS THROUGH PARTNERSHIP

---

FLASCO excels in cultivating strategic partnerships to further its mission. Through relationship building and insightful visits to our member's clinics, our organization actively seeks opportunities to engage with industry stakeholders, healthcare professionals, and community leaders to strengthen alliances that advance cancer care and support.



Through purposeful engagement, FLASCO gains firsthand insights into healthcare facilities and initiatives, facilitating a comprehensive understanding of the challenges in the healthcare and oncology industry. FLASCO's Professional Partnership Program is designed to foster mutually beneficial relationships. By joining forces, we can create new opportunities, leverage each other's strengths, and drive innovation.

# MEASURING PROGRESS THROUGH NEW INITIATIVES

## PROFESSIONAL PARTNERSHIP PROGRAM


At FLASCO, we believe in the power of collaboration and building strong alliances to achieve shared success. Through this partnership, we will increase engagement and collaboration with oncology professionals and provide important benefits to enrolled FLASCO members at participating private practices, hospitals, and academic centers.



[Learn About FLASCO's NEW Professional Partnership Program HERE >>](#)

## NEURO-ONCOLOGY CONSORTIUM

The Neuro-Oncology Consortium was developed to bring together thought leaders to further the understanding and awareness of brain cancer, and drive research and innovation towards advancements in neuro-oncology treatments and therapies.



## PEDIATRIC ONCOLOGY CONSORTIUM

The goal of the Pediatric Oncology Consortium is to establish a strong network of pediatric oncology professionals to communicate and collaborate on furthering cancer research, education, advocacy, and empowerment in all aspects of pediatric oncology.



# MEASURING PROGRESS THROUGH MEMBERSHIP

In 2023, FLASCO experienced remarkable growth in its membership, reflecting a flourishing community dedicated to advancing cancer care and advocacy. As we reach more individuals with the value of FLASCO's mission, our diverse membership base has expanded significantly.



This surge in membership not only signifies the organization's growing influence but also underscores the trust and confidence that individuals place in FLASCO as a pivotal force in shaping the future of cancer-related initiatives.

The growth in FLASCO's membership would not be possible without the **2023 FLASCO Membership Committee**: Chariman **Dina Dumercy McHenry, PharmD, BCOP, BCPS**; Co-Vice Chairman **Mehdi Moezi, MD**; & Co-Vice Chairman **Cheryl Habue, MSN, RN, CCRP**.

| Membership Type                       | Active Members 2021 | Active Members 2022 | Active Members 2023 |
|---------------------------------------|---------------------|---------------------|---------------------|
| Regular Members                       | 1823                | 1921                | 2021                |
| Associate & Student Associate Members | 93                  | 178                 | 197                 |
| Affiliate Members                     | 1633                | 1943                | 1946                |
| Courtesy Members                      | 227                 | 294                 | 326                 |
| <b>Total Members</b>                  | <b>3776</b>         | <b>4336</b>         | <b>4490</b>         |

# MEASURING PROGRESS THROUGH ACTION

## ADVOCACY AT FLASCO

The impactful, and at times controversial, 2023 legislative session in Florida kept the FLASCO Legislative Committee busy in 2023. Before the start of session, Governor Ron DeSantis unveiled a legislative proposal to reign in unchecked Pharmacy Benefit Managers (PBMs) and drive transparency among prescription drug prices. The legislature passed the Prescription Drug Reform Act to support this initiative. SB 1550 addresses PBMs from all sides by requiring prescription drug manufacturers to disclose, and publish on the Florida Health Finder website. Several FLASCO members were crucial parts of this legislative victory, including testifying in front of the Florida Congress, contacting their state legislators, and educating their patients on the importance of this issue and how to contact their legislators.

FLASCO leverages our close partnerships with national societies, including ASCO, ASH, COA, NCCN, and ACCC to create opportunities for FLASCO members to impact National policy issues. In 2023, FLASCO members met with their US Senators and Representatives to discuss:

- Improving patient access to care by addressing prior authorization delays for essential medical services.
- Prohibiting copay accumulator programs, which often impact the most vulnerable patient populations, by requiring health plans to count the value of copay assistance payments toward a patient's out-of-pocket costs.
- Supporting cancer research and the National Cancer Plan through increased budgets for the National Institutes of Health (NIH), for the National Cancer Institute (NCI), and the Advanced Research Projects Agency for Health (ARPA-H)



# ADVOCACY AT FLASCO

The FLASCO Living With Series are educational programs focused on patient advocacy, conducted virtually and across Florida, catering to individuals dealing with diverse forms of cancer. These programs aim to unite cancer patients, caregivers, support groups, oncology experts, professionals, and industry supporters, fostering the exchange of essential information regarding various cancer types.



## This year, FLASCO hosted the following Living With programs:

**Living With Multiple Myeloma - February 16, 2023**

**Living With Prostate Cancer - February 25, 2023**

**Living With Colorectal Cancer - May 4, 2023**

**Living With Polycythemia Vera - May 10, 2023**

**Living With GIST - June 8, 2023**

**Living With Prostate II - August 30, 2023**

**Veterans Living With Cancer - September 23, 2023**

**Living With Systemic Mastocytosis - October 14, 2023**

**Living With Lung Cancer - December 7, 2023**

**Living With Chronic Lymphocytic Leukemia - December 14, 2023**

**590**  
PATIENTS &  
CAREGIVERS  
EDUCATED



(VIRTUAL & IN-PERSON IN 2023)




# ADVOCACY AT FLASCO

## Veterans Living With Cancer – September 23, 2023

This year, FLASCO launched its Inaugural Veterans Living With Cancer program. We are deeply grateful for the tremendous support it received in aid of our Veterans.

Through the support of Genentech, AstraZeneca, Amgen Oncology, American Cancer Society, and The Leukemia & Lymphoma Society, and their invaluable contributions, this program became a reality. Special thanks extended to the Summer JROTC Cadets, K9s For Warriors, University of South Florida School of Medicine, and the Yoga Veteran Project for their outstanding presentations and simulations.

The all-encompassing program presented a wide array of topics and activities. These included, but were not limited to, an overview of blood, lung, and prostate cancer, a Musical Journey of Healing, the Presentation of Colors & the National Anthem by the JROC Cadets of Lennard High School, a segment on Nutrition & Wellness highlighting the preparation of recipes, a simulated chair yoga session, a segment on Becoming Your Own Advocate, and the involvement of K9's For Warriors, sharing extraordinary stories of service animals and their significant role in the lives of veterans.




**Check Out the  
FLASCO  
Living With  
Series  
On YouTube!**

The complex block features a dark blue background. On the left is a screenshot of a YouTube channel page for "FLASCO Living With Series". The page shows a "Play all" button and several video thumbnails with titles like "Strategies to Prevent Cancer...", "Living with Ovarian Cancer", "Florida Society of Clinical Oncology", and "FLASCO Urology Collaborative". On the right, the text "Check Out the FLASCO Living With Series On YouTube!" is written in white and yellow.

# COMMUNICATION AT FLASCO

FLASCO's Social Media is a dynamic and interactive online community that brings together individuals impacted by cancer, healthcare professionals, and organizations dedicated to the field of oncology.

From educational resources to advocacy initiatives, our social media platforms offer a unique opportunity to connect with a diverse and passionate community.



## Follow Your State Society Social Media & Communication Pages!

**LinkedIn:** [Florida Society of Clinical Oncology](#)

**Twitter:** [@FLASCO\\_ORG](#)

**Facebook:** [Florida Society of Clinical Oncology](#)

**Instagram:** [@flasco\\_voiceofoncology](#)

**YouTube:** [@FLASCO\\_VoiceofOnc](#)

 **Click to  
Follow  
FLASCO!**

ENGAGE WITH  
YOUR ONCOLOGY  
COMMUNITY

**4006**

DOCMATTER  
MEMBERS

**47**



FLASCO  
NEWSLETTERS

**2319**



LINKEDIN  
REACTIONS

**799**



NEW LINKEDIN  
FOLLOWERS

**90**

YOUTUBE  
SUBSCRIBERS

**505**



INSTAGRAM  
LIKES

**4.5K**



FACEBOOK  
IMPRESSIONS

# FLASCO FRONTLINE

In 2024, FLASCO is introducing the revamped eNewsletter, the **FLASCO Frontline**, your go-to source for the latest in oncology! Dive into the vibrant new look as FLASCO continues to deliver cutting-edge insights and research highlights straight to your inbox. Stay at the forefront of oncology with the refreshed *FLASCO Frontline* – where innovation meets information!



## FLASCO FORUM POWERED BY DOCMATTER

Explore the FLASCO Forum on DocMatter – your hub for all things oncology. With a whopping 438+ posts, 406,000+ total views, and 3,900+ members in 2023, the opportunities to connect with FLASCO members are endless!

Thank you to the Advisory Board, a group of FLASCO Members that work with DocMatter to keep the conversation going, advise, answer questions, and work to develop an engagement strategy to ensure the FLASCO Forum is reflective of the topics being discussed in oncology and apply to all segments of the FLASCO membership.

Discover the latest and greatest in oncology at [DocMatter.com/FLASCO](https://DocMatter.com/FLASCO)




### Join the Conversation

*FLASCO Forum,  
Hosted on DocMatter*

 438+ POSTS

 406,000+ TOTAL VIEWS

 3,900+ MEMBERS



[DocMatter.com/FLASCO](https://DocMatter.com/FLASCO)


# FOSTERING THE FUTURE

Ensuring the future availability of quality cancer care for Floridians, FLASCO dedicates itself to supporting the talented oncologists of tomorrow.

FLASCO has a very active Oncology Fellow and Resident Program. FLASCO leverages [our network of experienced oncology professionals to provide mentorship, career advice, and education about real-world topics not covered in their training programs.

FLASCO supports cancer research by donating funds to the ASCO Conquer Cancer Foundation every year to provide a Young Investigator Award (YIA) in the amount of \$50,000 to a Florida Fellow each year.

As outlined in our mission statement, FLASCO is to promote accessibility to high-quality cancer care. FLASCO consistently works towards achieving this objective by granting Travel Awards to its Associate and Affiliate Members. These awards enable members to engage in national oncology meetings, facilitating additional education and networking opportunities within the field of oncology.



## 2023 Conquer Cancer Young Investigator Award

**Yumeng Zhang, MD**

**Moffitt Cancer Center & Research Institute,  
University of South Florida**

## 2023 FLASCO Travel Award Recipients

2023 PHARMACY TRAVEL AWARD RECIPIENT



MEENA MANEPALLI, PHARM D  
MIAMI CANCER INSTITUTE

2023 PHARMACY TRAVEL AWARD RECIPIENT




OMANI MCLISH, PHARM D  
MEMORIAL CANCER INSTITUTE

2023 PHARMACY TRAVEL AWARD RECIPIENT




CHLOE BAOTRAN HUYNH, PHARM D  
MEMORIAL CANCER INSTITUTE

2023 PHARMACY TRAVEL AWARD RECIPIENT




MIN KIM, PHARM D  
MEMORIAL CANCER INSTITUTE

2023 PHARMACY TRAVEL AWARD RECIPIENT



DIEU UYEN VU, PHARM D  
MEMORIAL CANCER INSTITUTE

2023 PHARMACY TRAVEL AWARD RECIPIENT



PAOLO SCALLA, PHARM D  
MIAMI CANCER INSTITUTE

2023 PHARMACY TRAVEL AWARD RECIPIENT



JOHN LEE, PHARM D  
MIAMI CANCER INSTITUTE

2023 PHARMACY TRAVEL AWARD RECIPIENT




MARY VOGEL, PHARM D  
MIAMI CANCER INSTITUTE

2023 PHARMACY TRAVEL AWARD RECIPIENT



EVESHA BRYAN, PHARM D  
MIAMI CANCER INSTITUTE

2023 ASTRO TRAVEL AWARD RECIPIENT




MOHAMED MOHANNA, MD  
CLEVELAND CLINIC

2023 ASTRO TRAVEL AWARD RECIPIENT



MAYANK PATEL, MD  
UNIVERSITY OF MIAMI

2023 ASTRO TRAVEL AWARD RECIPIENT



OMER SAIF, MD  
MAYO CLINIC FLORIDA

2023 ASCO TRAVEL AWARD RECIPIENT



PATRICIA BARRETO-COELHO, MD  
UNIVERSITY OF MIAMI

2023 ASCO TRAVEL AWARD RECIPIENT



LEIGHON ELLIOTT, MD  
UNIVERSITY OF FLORIDA

2023 ASCO TRAVEL AWARD RECIPIENT




SHENDUO LI, MD  
MAYO CLINIC FLORIDA

2023 ASCO TRAVEL AWARD RECIPIENT



TURAB MOHAMMED, MD  
MOFFITT CANCER CENTER

2023 ONS TRAVEL AWARD RECIPIENT



NICOLE SAUNIN, RN  
FLORIDA CANCER SPECIALISTS

2023 PHARMACY TRAVEL AWARD RECIPIENT



MANJIV PATEL, PHARM D  
MIAMI CANCER INSTITUTE

*Congratulations, 2023 Travel Award Recipients!*

# FLASCO COMMITTEES

FLASCO's strength lies in the active participation of member volunteers who contribute their time, effort, and expertise to advance the Society's operations and initiatives. Presently, there are nine FLASCO standing committees.

Scan the QR Code to learn more about FLASCO's Committees & Working Groups.



## CLINICAL PRACTICE COMMITTEE

The Clinical Practice Committee compiles, monitors, and maintains a library of oncology clinical practice parameters. The committee will act as a liaison with other agencies that deal with practice parameters and will serve as a resource to the membership.

The **2023 FLASCO Clinical Practice Committee** was headed by Chairman **Jorge Garcia, PharmD, MD, MHA, MBA, FACHE**; Co-Vice Chairmen **Hayder Saeed, MD** & **Fernando Vargas, MD**.

The crippling drug shortage crisis was the priority for the FLASCO Clinical Practice Committee in 2023. Acute shortages of many critical cancer drugs forced oncology clinicians to decide which of their patients received the recommended therapy, and which had their care delayed, or received alternative treatments. The Clinical Practice Committee worked to keep the FLASCO Members informed of the latest clinical guidelines for drug shortage issues released from our national partner organizations such as ASCO and NCCN.



# DISPARITIES COMMITTEE

The FLASCO Disparities Committee was established in 2019. The goal of this committee is to narrow the disparity in cancer patients in Florida in-line with the Healthy People 2030 national program. They focus their work on five key areas: **Awareness, Advocacy, Access, Research, & Education**. The **2023 FLASCO Disparities Committee** was headed by Chairman, **Jose Sandoval-Sus, MD**, & Vice Chairman, **Kathy Fu, MD**.


|  |  |  |  |   |
|--|--|--|--|---|
| <br><b>AWARENESS</b><br>Continue Disparity & Health Equity Webpage with updates on cancer disparity news & publications | <br><b>ADVOCACY</b><br>Recommend all FLASCO sponsored programs have a statement on cancer disparity or health equity. | <br><b>RESEARCH</b><br>Curate publications to the Disparity & Health Equity webpage | <br><b>EDUCATION</b><br>Promote the FLASCO Cancer Disparities Summit | <br><b>WORKFORCE DIVERSITY</b><br>Offer Disparities travel grant and poster presentations for the Cancer Disparities Summit. Continue highlighting FLASCO members in cancer disparity and health equity. |
|--|--|--|--|---|

In 2023, The FLASCO Disparities Committee coordinated an exclusive interview with a distinguished guest: **Lynn Schuchter, MD, FASCO**, the **President of American Society of Clinical Oncology (ASCO)**

This insightful conversation delves into the critical topic of healthcare disparities, exploring the challenges, opportunities, and groundbreaking initiatives aimed at achieving health equity in our communities.

Dr. Lynn Schuchter brings a wealth of experience and expertise to the table, and we were privileged to have her share her valuable insights on this pressing issue that affects Americans battling cancer.

[Watch the Interview HERE >>](#)



*Discussing*  
**Disparities**

An Interview With ASCO President, Lynn Schuchter, MD, FASCO

“ My presidential theme for ASCO is the **Art and Science of Cancer Care**, from comfort to care, and that theme encompasses the excitement of oncology in driving new therapies and new cures but understanding that our therapies don't benefit every patient. So how can we do better - how can we help?

Lynn Schuchter, MD, FASCO  
ASCO President



# PROGRAM COMMITTEE

The Program Committee formulates and organizes the scientific programs associated with the Society's meetings. The **2023 FLASCO Program Committee** was led by Chairman **Chakra Chaulagain, MD, FACP**; Co-Vice Chairman **Manmeet S. Ahluwalia, MD, MBA**; Co-Vice Chairman **Jessica McMillan, DNP, FNP, APRN-BC**; & Co-Vice Chairman **Joseph Rosenblatt, MD**. The following is an overview of the FLASCO Events curated by the Program Committee in 2023.

| Program Name  | 2023 Program Attendees |
|---|------------------------|
| Early Lung Summit                                   | 164                    |
| Puerto Rico Oncology Symposium                      | 201                    |
| Fellows & Residents Training Program                | 106                    |
| Great Strides Together                              | 114                    |
| Rapid Integrations                                  | 114                    |
| FLASCO Spring Session & Business of Oncology Summit | 451                    |
| FLASCO Fall Session                                 | 628                    |
| Cancer Disparities & Health Equity Summit           | 192                    |

# EARLY LUNG SUMMIT

FLASCO remains committed to its mission by providing education, support, and resources for healthcare professionals, patients, and the public in the field of oncology, including lung cancer.

Held on January 20-21, 2023 in Hollywood, Florida, the Early Lung Summit brought together a diverse array of experts, researchers, clinicians, and advocates dedicated to advancing our understanding and treatment of lung cancer. This 3rd Annual Early Lung Summit emphasized the Challenges of Early Detection.

Renowned expert speakers took center stage, delving into a spectrum of Multi-Disciplinary topics related to Lung Health, Lung Screenings, Best Practices, CT Screening, Blood Biomarkers, and beyond.

FLASCO would like to sincerely thank the program chair, **Luis Raez, MD, FACP, FCCP**, faculty, program attendees, exhibitors, and sponsors, AstraZeneca, Merck, & Regeneron, for their commitment in the fight against lung cancer. As we look ahead, the insights gained from this summit will undoubtedly shape the trajectory of lung cancer research and treatment in the coming years. This program is held bi-annually and will resume in 2025.





# PUERTO RICO ONCOLOGY SYMPOSIUM

On February 3-4, 2023, FLASCO, in collaboration with AHOMPR, held the 12th Annual Puerto Rico Oncology Symposium in San Juan, Puerto Rico.

The objective of this conference was to update hematologists/oncologists and their teams on issues affecting practices in the USA and Puerto Rico. This conference also helped advance the understanding of, and ultimately help to eliminate, the disparities along the cancer continuum that represent a significant public health problem. Our ultimate goal of this educational effort is to promote collaborations between leading cancer care disparities scientists in mainland USA and Puerto Rico.

FLASCO extends a thank you to the Program Chair **Gerardo Colon-Otero, MD**, faculty, program attendees, exhibitors, and sponsor, Gilead!




# ONCOLOGY FELLOWS & RESIDENTS EDUCATIONAL TRAINING PROGRAM

On March 25, 2023, FLASCO hosted a one-day educational program in Orlando, with respected keynote speakers from Florida oncology practices to share helpful information and essential tools for Fellows, as they transition into the oncology workforce.

Topics of the program included: Bench to Bedside, Immunotherapies, Contract Negotiation, Billing, Reimbursement & Telehealth, Career Pathways and Collaboration, and a Panel Discussion with Academia, Community & Industry.

Thank you to the Program Chair, **Rick McDonough, MD**, program attendees, exhibitors, and sponsors: Bristol Myers Squibb & Eisai!



# GREAT STRIDES TOGETHER & RAPID INTEGRATIONS

The Great Strides Together conference is a well-established, multi-facility meeting for oncology professionals, with a focus on Advanced Practice Providers. Over the past 12 years, it has consistently delivered a state-of-the-art educational experience, emphasizing collaborative efforts within the Oncology provider team of the physician and APP to enhance patient-focused standard of care education and improve cancer treatment outcomes.

The FLASCO Rapid Integration Course is an educational initiative for clinicians new to the area of hematology/oncology. The goal of this course is to close the gap of knowledge for these new providers and to provide skills that are important in a hematology-oncology practice by rapidly integrating them into the oncology workforce.

This program was held on May 13, 2023 at the Lakeland Regional Health Hollis Cancer Center. Thank you to **Lakeland Regional Health Hollis Cancer Center** for your hospitality in hosting FLASCO and your contribution to the program's success.



# BUSINESS OF ONCOLOGY SUMMIT

On April 14, 2023, FLASCO held its annual Business of Oncology Summit, designed with industry, medical provider, patient, and payor in mind, to provide the opportunity for communication and collaboration.



This summit provided an emphasis on the business of oncology that focuses on specific financial-driven business topics addressing the current and future challenges in the landscape of cancer care.

The theme for the Business of Oncology Summit was “EOM – The Good, The Bad, The Ugly.” FLASCO extends a thank you to the Business of Oncology Summit chairs, **Thomas Marsland, MD** & **Michael Kolodziej, MD**, faculty, attendees and exhibitors!



# SPRING SESSION

On April 14-15, 2023, FLASCO held its annual Spring Session. The Spring Session is a clinical focused meeting for physicians, advance practice providers, nurses, administrators, pharmacists, social workers, and financial counselors.

The 2023 FLASCO Spring Session hosted presentations and discussion panels on Bi-specific Immunotherapy in Myeloma, Advances in Bi-specific Antibody Treatment in B cell NHL, Her-2 in Cancer: An Update in Therapeutic Implications of HER-2 Pathway in GI and Lung Cancers, and An Update on HPV-Driven Head, Neck, and Gynecologic Cancers, and more.



The society extends a warm thank you to all 2023 FLASCO Spring Session faculty, attendees, and exhibitors.



# FLASCO FOUNDATION

FLASCO Foundation, Inc. the philanthropic arm of the Florida Society of Clinical Oncology, provides Florida cancer patients, families, caregivers and survivors, access to the best educational, social, financial, and emotional support services available.



FLASCO Foundation leverages its statewide footprint to forge robust collaborations to reach those in need.

FLASCO Foundation provides funding for partner organizations that offer a wide range of social services and compassionate assistance to those who are faced with the challenges of this disease.

In support of it's Mission, each year the FLASCO Foundation offers grants to Florida organizations providing outreach and support to Florida's cancer patients.

**The FLASCO Foundation donated \$30,000 to cancer-focused, Florida-based nonprofits in 2023.**

## FLASCO FOUNDATION GALA

This year's FLASCO Foundation Gala, held on April 14, 2023, was a roaring 20's success with themed attire, entertainment, and fundraising!

**Rick McDonough, MD,** was presented the Dorothy Green Phillips Legacy Award by the FLASCO Foundation.

**FLASCO Foundation raised \$23,000 at the 2023 FLASCO Foundation Gala.**

[\*\*VIEW THE FLASCO FOUNDATION GALA VIDEO>>\*\*](#)



# FALL SESSION

FLASCO hosted the Fall Session on October 20-21, 2023 in Orlando, Florida. This meeting was designed for oncology providers and emphasized multidisciplinary collaboration among all professional healthcare teams with dynamic educational tracks that focused on the latest scientific advancements addressing the current and future changes in cancer care delivery.




The Fall Session featured five scientific educational tracks: Multi-Disciplinary, Pharmacy, Advanced Practice Provider, Nurse/Navigator, & Administrator. The commitment of the dedicated track chairs, **Chakra Chaulagain, MD, FACP**, **Jorge Garcia, PharmD, MS, MHA, MBA, FACHE**, **Jessica McMillan, DNP, ARNP**, **Delmarie Butler**, **Gail Erentreich**, and **Shelli Johnson**, respectively, provided an enriching experience for all participants. We appreciate your valuable contributions to FLASCO.



# CANCER CARE DISPARITIES & HEALTH EQUITY SUMMIT

On November 3-4, 2023, professionals from academia, industry, and the community came together with the shared mission of closing health equity gaps and developing and sustaining diversity and inclusion efforts in the health system of Florida. Together we promoted the exchange of novel ideas, discussed the latest findings in the field, and stimulated the development of new research, advocacy, and policy in cancer disparities.

This program would not be possible without the insightful planning of the Program Chair, **Luis Raez, MD, FACP, FCCP**, faculty, and the support of industry sponsors: Bristol Myers Squibb, Sanofi, AbbVie, Gilead, Janssen, & Merck!



# CORPORATE PARTNER INITIATIVES

Members and partners of FLASCO are characterized by their unwavering passion and a strong dedication to service, consistently bringing forward innovative ideas. Through collaborative efforts, we aim to activate strategic approaches that align with and advance the mission of FLASCO.

Over the past decade, FLASCO has demonstrated effectiveness in implementing various initiatives. This includes the organization of disease-specific educational seminars for patients and survivorship education programs across the state, and reducing gaps between clinical evidence and clinical practice in Florida.

In acknowledging the vital importance of extending our mission into the future, FLASCO is dedicated to continuing our mission of supporting cancer patients in Florida, driven by a collective determination to make a lasting impact on their lives.



**Thank you 2023 FLASCO Corporate Partners!**

# 2023 FLASCO CORPORATE PARTNERS



**AbbVie**  
**Alexion**  
**Amgen**  
**Astellas Pharma**  
**AstraZeneca**  
**Bristol-Myers Squibb**  
**Genentech**  
**GSK**  
**Incyte**  
**Merck**  
**Pfizer Oncology**  
**Puma Biotechnology**  
**Sanofi**  
**Seagen**  
**Takeda Oncology**



**BeiGene**  
**Boehringer Ingelheim**  
**Caris Life Sciences**  
**Daiichi Sankyo, Inc.**  
**Foundation Medicine**  
**Gilead**  
**Jazz Pharmaceuticals**  
**Kite Pharma**  
**Mirati Therapeutics**  
**Pharmacyclics**  
**PharmaEssentia**  
**Regeneron Pharmaceuticals**



**Adaptive Therapeutics**  
**ADC Therapeutics**  
**Blueprint Medicines**  
**CTI Biopharma**  
**Deciphera Pharmaceuticals**  
**Eisai**  
**EMD Serono**  
**Exelixis**  
**G1 Therapeutics**  
**Genmab**  
**GRAIL**  
**Guardant Health**  
**ImmunoGen**  
**Johnson & Johnson Innovative Medicine**  
**Karyopharm Therapeutics**  
**Lilly Oncology**  
**MacroGenics**  
**MorphoSys**  
**Novartis**  
**Recordati Rare Diseases**  
**Sumitomo Pharma America**  
**Taiho Oncology**



**Agios Pharmaceuticals**  
**AmerisourceBergen Oncology Supply**  
**Apellis Pharmaceuticals**  
**Aveo Oncology, an LG Chem company**  
**Biotheranostics A Hologic Company**  
**Blue Earth Diagnostics, Inc.**  
**Castle Biosciences**  
**Celltrion**  
**Coherus Biosciences**  
**Exact Sciences**  
**Immunocore, LLC**  
**IPSEN BioPharmaceuticals**  
**Natera**  
**Rigel**  
**Servier**  
**Sobi, Inc.**  
**Stemline, a Menarini Company**


# CORPORATE PARTNER INITIATIVES

**BiSpecific Collaborative** - Ensuring that these drugs can be safely delivered to patients in the academic centers and in the community is critical for patient access. FLASCO hosted roundtable discussions of key thought leaders from academic, hospital, and community based practices to discuss and align on challenges and educational gaps as it relates to Bispecifics, including adverse event management, sharing best practices, and aligning on how FLASCO can support educational needs.

**Testing Gaps in mCRC** - FLASCO Member's throughout the State of Florida have agreed that routine testing for Precision Medicine is a priority, specifically in mCRC BRAF V600E patients, but the process following the testing has consistent gaps. This initiative worked to identify best practices and interventions that can both identify the causes for unwarranted variations of care in the testing and treatment of mCRC BRAF V600E to improve the testing process and timeliness of guideline concordant care.

**Collaborative Approach to Screening for PNH High Risk Groups** - FLASCO worked to identify current PNH testing trends in Florida through a survey. Provided awareness on independent ICCS testing guidelines and engage with FLASCO participants to capture best practices in optimizing testing process with the goal of increasing awareness and adoption rate for ICCS guideline-based testing and re-testing with HSFC-PB for PNH

**Project ACE** - Understanding and supporting ACcEss needs for patients throughout insurance transition. Connected industry partners with oncology administrators to utilize this discussion to find gaps in available resources for patients and their clinicians when navigating an insurance transition (ie commercial to Medicare) while undergoing cancer treatment. Will work to co-develop education materials for patients going through an insurance transition.



# CORPORATE PARTNER INITIATIVES


## **Understanding Behavioral Drivers Associated with Treatment Decision**

- Making and Adherence Among Patients with Metastatic Breast Cancer and Metastatic Bladder Cancer : A Qualitative Study of Patients Navigating Cancer Care in Florida. FLASCO will explore and assess the impact of the patient-provider relationship, including the impact of communication and shared decision-making on a patient's treatment decision making and preferences. With the goal to identify strategies that may improve communication, information seeking and other salient considerations of interest from the perspective of patients throughout the treatment journey

**Testing Assessment** – FLASCO conducted a survey covering various aspects related to HER2 and CD30 testing and assessment, including familiarity with the testing methods, frequency of testing in clinical practice, and clinicians' experience with administering targeted therapies based on the test results. The survey questions aim to understand if HER2 assessment is being performed in mCRC and if CD30 assessment of T cell and B cell lymphomas is being performed.

**Ask the Experts: HER2+ Breast Cancer** – Provided patient education for HER2+ Breast Cancer. The goal of this series was to bring together HER2+ Breast Cancer patients and caregivers to allow them to ask our experts questions regarding their HER2+ breast cancer diagnosis and provide education regarding available treatment options.

**Identifying Patients with Advanced PV** – Quality initiative to identify and provide standard of care to patients with advanced PV. Share how to utilize data and EHRs to understand patient populations that newly released clinical data could impact their treatment journey.



# FLASCO

2023: A YEAR BY THE NUMBERS

# 1977

YEAR ESTABLISHED



# 4,300+

 SOCIAL MEDIA FOLLOWERS

SOCIAL MEDIA FOLLOWERS



# 66

 CORPORATE PARTNERS

# 4490

 FLASCO MEMBERS

FLASCO MEMBERS



# 1856

ATTENDEES

# 8

FLASCO ANNUAL MEETINGS



# 19

CO-PARTNERED MEETINGS

# 10

 LIVING WITH PROGRAMS

# 315

EXHIBITORS & SPONSORS

# 69000

WWW.FLASCO.ORG PAGE VIEWS



# 24800

WWW.FLASCO.ORG USERS FROM THE US, PR, GERMANY, INDIA, UK, & CANADA



GRATITUDE FOR OUR MEMBERS, PARTNERS, & COLLEAGUES